Live Chat

Pfizer shares sink as revenue prospects

Pfizer shares slide as revenue, profit forecasts fall below Wall Street expectations

On Wednesday, pharmaceutical giant Pfizer projected 2024 revenue and profit below Wall Street's expectations, resulting in a 9% decline in the PFE share price, despite an increase in the firm’s cost-cutting target by $500 million.

A decrease in annual COVID vaccination rates and demand for treatments in 2023 has impacted the sales of Pfizer's COVID products, including Paxlovid and the vaccine Comirnaty. These products, which significantly contributed to its revenue in the past two years, are now expected to generate $8 billion in total sales in 2024.

The same concerns have plagued other drugmakers whose shares surged during the pandemic. Moderna shares dropped by 4.1%, and Pfizer's German partner in the vaccine, biotech firm BioNTech SE, saw a 3.9% decline in premarket trading.

Fizer has also faced challenges due to a significant decrease in sales of its COVID-19 vaccine and its antiviral pill Paxlovid, both of which contributed to generating over $100 billion in revenue last year.

Analysts had anticipated sales of Comirnaty alone to exceed $8 billion, in addition to more than $5 billion from Paxlovid. The decline in COVID product sales prompted Pfizer to slash its headcount and expenses, expected to save at least $4 billion annually. In November, the company cut 500 jobs at its Sandwich, Kent site in the UK.

The move appears to have done little to reassure investors, with New York-listed Pfizer shares shedding close to 9% in Wednesday trading. To make up for the shortfall in its pipeline, the U.S. drug manufacturer announced its plans to buy Seagen, an oncology drugmaker, for $43 billion earlier this year.

Choose your points of movement

Сalculate your hypothetical P/L (aggregated cost and charges) if you had opened a trade today.

Market

Shares Search
Shares
Index
Commodity
Bonds
Crypto
ETFs
Currency

Instrument

Search
Clear input
Occidental
Prosus N.V.
Porsche AG
Hermes
CAT
Thermo Fisher
Nikola Corporation
Tilray
Shell plc (LSE)
Skillz Inc
Iberdrola
DeltaAir
CrowdStrike Holdings
Golar LNG
Applied Materials
Snowflake
Royal Bank Canada
Amazon.com
Spotify
Exxon Mobil
CCB (Asia)
McDonald's
Campari
GameStop
Netflix
ON Semiconductor
Costco
Dave & Buster's
Delivery Hero SE
LUCID
Continental
Zoom Video Communications
Schlumberger
Virgin Galactic
Upwork Inc.
Cameco
JP Morgan
Fuelcell
Rivian Automotive
XPeng Inc
Wal-Mart Stores
Trade Desk
Blackstone
Vodafone
Aptiv PLC
L'Oreal
Target
Rio Tinto
Sartorius AG
British American Tobacco
Qorvo
ASOS
Cisco Systems
Nel ASA
Arista
Airbus
Apple
Pfizer
AMC Entertainment Holdings
ASML
Hubspot
Teladoc
Starbucks
SMCI
Canopy Growth
Wish.com Inc
Lockheed Martin
ProSiebenSat.1
IAG
AbbVie
Marston's
Baidu
Teleperformance
Norwegian Air Shuttle
Airbus Group SE
HSBC HK
Block
Annaly Capital
Abbott
LVMH
American Express
Novavax
GoPro
Siemens
Total
SIG
Pinterest Inc
Taiwan Semi
Etsy
Amgen
SONY
3D Systems
UPS
BlackBerry
Gen Digital Inc
Xiaomi
Quanta Services
Unity Software
NVIDIA
Anglo American
Palantir Technologies Inc
Fresnillo
Deere
Rolls-Royce
Porsche
Uber
Vir Biotechnology
American Airlines
ROBLOX Corp
Macy's
FirstRand
easyJet
DISNEY
Aurora Cannabis Inc
BP
Adidas
Boeing Co
Vonovia
Coca-Cola Co (NYSE)
Home Depot
General Electric
Coinbase Inc
ALIBABA HK
Philip Morris
General Motors
PayPal
UniCredit
II-VI
BASF
Kraft Heinz
Alphabet (Google)
Palo Alto Networks
Plug Power
Li Auto
Oracle
Roku Inc
UiPath Inc
Upstart Holdings Inc
F5 Networks
Infinera
Inditex
ZIM Integrated Shipping Services Ltd
Deutsche Bank
Hammerson
IBM
JD.com
Barrick Gold
Lemonade
MerckCo USA
Infosys
Invesco Mortgage
Comcast
Santander
Accenture
Anheuser-Busch Inbev
Visa
Mastercard
T-Mobile
SAP
Wayfair
Beyond Meat
Kuaishou
CarMax
Tesla
Lyft
Medtronic
Adobe
Morgan Stanley
Workday Inc
Blackrock
Vipshop
Meta (Formerly Facebook)
Linde PLC
Micron
Lululemon
Ceconomy
Chipotle
Gilead
Naspers
Bristol Myers
The Cheesecake Factory
Glencore plc
British American Tobacco
ChargePoint Holdings Inc
Twilio
Intel
Lloyds
CNOOC
Electrolux
Wells Fargo
Sea
PG&E
Fedex
Citigroup
Peloton Interactive Inc.
eBay
Microsoft
JnJ
Bilibili Inc
Trump Media & Technology Group
AIA
Nasdaq
Air France-KLM
Allianz
Lithium Americas Corp
Procter & Gamble
Qualcomm
AMD
New Oriental
MercadoLibre.com
Mondelez
Lumentum Holdings
Two Harbors Investment aration
AstraZeneca
Norwegian Cruise Line
Unilever
GoHealth
PepsiCo
Barclays
PETROCHINA
Goldman Sachs
Eli Lilly
HSBC
Cellnex
Berkshire Hathaway
Jumia Technologies
HDFC Bank
RTX Corp
Bayer
Bank of America
Chevron
ADT
DoorDash
Marriott
Nike
AT&T
GSX Techedu
Robinhood
Telecom Italia
Deliveroo Holdings
TUI
Freeport McMoRan
Toyota
BioNTech
Airbnb Inc
Alibaba
Verizon
Nio
Eni
Ford
Volkswagen
UnitedHealth
Shopify
China Life
Snap
Christian Dior
Conoco Phillips
Lufthansa
Tencent
Moderna Inc
Salesforce.com
Broadcom
Diageo
Toro
Cinemark

Account Type

Direction

Quantity

Amount must be equal or higher than

Amount should be less than

Amount should be a multiple of the minimum lots increment

USD Down
$-

Value

$-

Commission

$-

Spread

-

Leverage

-

Conversion Fee

$-

Required Margin

$-

Overnight Swaps

$-
Start Trading

Past performance is not a reliable indicator of future results.

All positions on instruments denominated in a currency that is different from your account currency, will be subject to a conversion fee at the position exit as well.

Seagen acquisition: Pfizer to acquire cancer drugmaker for $43 billion

Pfizer's $43 billion deal to acquire Seagen, expected to close on Thursday, is projected to add $3.1 billion to revenue next year. The company intends to establish an oncology division in early 2024, led by Chris Boshoff, the current head of cancer research and development for Pfizer.

The U.S. drugmaker anticipates its annual revenue to fall within the range of $58.5 billion to $61.5 billion, compared to analysts' average estimate of $63.17 billion, according to LSEG data.

Pfizer also forecasts an adjusted profit in the range of $2.05 to $2.25 per share — lower than analysts' expectations of $3.16.

Pfizer share price forecast: Most analysts still bullish on PFE stock

Pfizer shares had a consensus Moderate Buy rating as of December 13, according to 14 analysts surveyed by TipRanks offering 12-month price targets on PFE stock. The average price target was $39.73 (a potential 52.75% upside from the stock’s current price), with a high forecast of $75.00 and a low forecast of $25.99.

Goldman Sachs analyst Chris Shibutani remained upbeat about PFE’s prospects, reaffirming a Buy rating on the stock on December 12.

Shibutani believes that the successful conclusion of the “Seagen transaction is an important milestone for Pfizer and meaningfully improves PFE’s end-of-decade revenue outlook.” The analyst also stressed that Seagen’s offerings are backed by compelling clinical data, fueling optimism about Pfizer’s prospects after the deal closes.

At the time of writing on Wednesday, Pfizer shares were trading at $26.01, down over 9% on the day. The pharma giant’s stock has taken a hit this year and is down over 49% year-to-date. PFE’s trajectory has run in stark contrast to the U.S. stock market, with the benchmark S&P 500 index gaining over 21% this year so far.

When considering shares for trading and price predictions, remember that trading CFDs involves a significant degree of risk and could result in capital loss.

Past performance is not indicative of any future results. This information is provided for informative purposes only and should not be construed to be investment advice.

Latest news

Wall Street's leading indices notch fresh records ahead of US inflation data release later today

Thursday, 10 October 2024

Indices

Wall St. soars to new highs ahead of US inflation report

Wednesday, 9 October 2024

Indices

Hang Seng index surges, breaking 21,000 mark

Wednesday, 9 October 2024

Indices

Dow Jones index today: Dow Hit Record Closing Highs

Wednesday, 9 October 2024

Indices

Nvidia stock surges 4% in Tuesday, notching its fifth straight day of gains

Live Chat